Intrabiotics Pharamceuticals, Inc. Form 8-K
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
             
    Date of Report (Date of earliest event reported):   August 13, 2003    
       
   

IntraBiotics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)
         
Delaware   000-29993   94-3200380
 
 
(State or other jurisdiction
of incorporation)		   (Commission
File Number) 		  (IRS Employer
Identification No.)
         
2483 East Bayshore Road, Suite 100, Palo Alto, California     94303  
   
 
(Address of principal executive offices)     (Zip Code)  
       
Registrant’s telephone number, including area code:   (650) 526-6800
   
 
Not Applicable
(Former name or former address, if changed since last report)

 

TABLE OF CONTENTS

Item 12. Results of Operations and Financial Condition.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Table of Contents

Item 12. Results of Operations and Financial Condition.

     On August 13, 2003, IntraBiotics Pharmaceuticals, Inc. publicly disseminated a press release announcing certain financial results for the quarter ended June 30, 2003. A copy of the press release with respect to this matter is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

     The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by IntraBiotics Pharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

       
    INTRABIOTICS PHARMACEUTICALS, INC.
     
Date: August 14, 2003   /s/ Eric H. Bjerkholt
   
    Eric H. Bjerkholt
    Sr. Vice President and Chief Financial Officer

 

Table of Contents

EXHIBIT INDEX

     
Number   Description
 
99.1   Press Release entitled “IntraBiotics Reports Second Quarter 2003 Financial and Operating Results,” dated August 13, 2003.